These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 22077267)

  • 1. Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: French healthcare payer perspective.
    Luporsi E; Mahi L; Morre C; Wernli J; de Pouvourville G; Bugat R
    J Med Econ; 2012; 15(2):225-32. PubMed ID: 22077267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France.
    Bourguignon S; Faller M; Champs FO; Moutier H; Levesque K; Caranhac G; Cohen-Solal A
    ESC Heart Fail; 2019 Jun; 6(3):559-569. PubMed ID: 31021531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy.
    Rognoni C; Ortalda V; Biasi C; Gambaro G
    Adv Ther; 2019 Nov; 36(11):3253-3264. PubMed ID: 31489572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of implementing ESC guidelines for treatment of iron deficiency in heart failure in the Nordic countries.
    Hofmarcher T; Cabrales Alin D; Linde C
    Scand Cardiovasc J; 2018 Dec; 52(6):348-355. PubMed ID: 30457358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
    Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
    Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective.
    Bager P; Dahlerup JF
    J Crohns Colitis; 2010 Oct; 4(4):427-30. PubMed ID: 21122539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Economic impact of ferric carboxymaltose in haemodialysis patients].
    Aiello A; Berto P; Conti P; Panichi V; Rosati A
    G Ital Nefrol; 2020 Aug; 37(Suppl 75):. PubMed ID: 32749086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
    Toblli JE; Di Gennaro F
    PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia.
    Szucs TD; Blank PR; Schwenkglenks M; Aapro M
    Oncology; 2011; 81(1):45-9. PubMed ID: 21921645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
    Pollock RF; Muduma G
    Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of anemia in advanced breast and lung cancer patients in daily practice: results of a French survey.
    Ray-Coquard I; Morère JF; Scotté F; Cals L; Antoine EC
    Adv Ther; 2012 Feb; 29(2):124-33. PubMed ID: 22314432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom.
    Pollock RF; Muduma G
    J Med Econ; 2020 Jul; 23(7):751-759. PubMed ID: 32208038
    [No Abstract]   [Full Text] [Related]  

  • 13. Financial impact of intravenous iron treatments on the management of anaemia inpatients: a 1 year observational study.
    Delpeuch A; Ruivard M; Abergel A; Aumaitre O; Boisgard S; Bagel S; Sautou V
    Int J Clin Pharm; 2018 Jun; 40(3):686-692. PubMed ID: 29520555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a multifaceted intervention to promote the use of intravenous iron sucrose complex instead of ferric carboxymaltose in patients admitted for more than 24 h.
    Touchard J; Perrin G; Berdot S; Pouchot J; Loustalot MC; Sabatier B
    Eur J Clin Pharmacol; 2021 Feb; 77(2):189-195. PubMed ID: 32926203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden.
    Hofmarcher T; Borg S
    J Med Econ; 2015; 18(7):492-501. PubMed ID: 25766863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic.
    Wilson PD; Hutchings A; Jeans A; Macdougall IC
    J Med Econ; 2013; 16(1):108-14. PubMed ID: 22989163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of erythropoiesis-stimulating agents for anemia related to cancer.
    Klarenbach S; Manns B; Reiman T; Reaume MN; Lee H; Lloyd A; Wiebe N; Hemmelgarn B; Tonelli M
    Cancer; 2010 Jul; 116(13):3224-32. PubMed ID: 20564645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budget impact of parenteral iron treatment of iron deficiency: methodological issues raised by using real-life data.
    Brock E; Braunhofer P; Troxler J; Schneider H
    Eur J Health Econ; 2014 Dec; 15(9):907-16. PubMed ID: 24081613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose.
    Christoph P; Schuller C; Studer H; Irion O; De Tejada BM; Surbek D
    J Perinat Med; 2012 May; 40(5):469-74. PubMed ID: 22945271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.